Schizophrenia is a remarkably complex disorder with a multitude of behavioral and biological perturbations. Cognitive deficits are a core feature of this disorder, and involve abnormalities across multiple domains, including memory, attention, and perception. The complexity of this debilitating illness has led to a view that the key to unraveling its pathophysiology lies in deconstructing the clinically-defined syndrome into pathophysiologically distinct intermediate phenotypes. Accumulating evidence suggests that one of these intermediate phenotypes may involve phospholipid signaling abnormalities, particularly in relation to arachidonic acid (AA). Our data show relationships between levels of AA and performance on tests of cognition for schizophrenia patients, with defects in AA signaling associated with deficits in cognition. Moreover, dopamine may moderate these relationships between AA and cognition. Taken together, cognitive deficits, dopaminergic neurotransmission, and bioactive lipids have emerged as related features of schizophrenia. Existing treatment options for cognitive deficits in schizophrenia do not specifically target lipid-derived signaling pathways; understanding these processes could inform efforts to identify novel targets for treatment innovation.
KeywordsSchizophrenia; Neurocognitive deficits; Phospholipids; Arachidonic acid; Eicosanoids; Dopamine; Review
INTRODUCTIONSchizophrenia is one of the world's leading causes of disability (1). Despite the extensive research its etiology remains very poorly understood. Part of the difficulty arises from the striking diversity of the documented abnormalities that a theory of etiology must explain, including the cognitive deficits that are a core feature of the illness, as well as the myriad biochemical abnormalities that influence neurodevelopment, neurotransmission, and neuromodulation. The deficits in cognition produce substantial functional disability, which is reflected in high rates of unemployment and reduced financial competence. Given the range and severity of cognitive impairment, efforts are now underway to identify novel targets for pharmacological enhancement. The purpose of this review is to integrate recent conceptual and empirical advances that implicate cognitive disorder in schizophrenia as an Send correspondence to: Jeffrey K. Yao, VA Pittsburgh Healthcare System 151U-H, 7180 Highland Dr., Pittsburgh, PA 15206, USA, jkyao@pitt.edu.
NIH Public Access
Author ManuscriptFront Biosci (Schol Ed). Author manuscript; available in PMC 2011 March 18.
Published in final edited form as:Front Biosci (Schol Ed). ; 3: 298-330.
NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript outcome of compromises to interacting neurochemical systems. We first summarize the rationale for identifying cognitive disorder as a target for treatment innovation, including the rationale for focusing on specific domains of cognition. We next present the background for our hypothesized linkage of cognitive deficits, abnormalities in mem...